BRPI0606170A2 - purificação diastereomérica de rosuvastatina - Google Patents

purificação diastereomérica de rosuvastatina

Info

Publication number
BRPI0606170A2
BRPI0606170A2 BRPI0606170-2A BRPI0606170A BRPI0606170A2 BR PI0606170 A2 BRPI0606170 A2 BR PI0606170A2 BR PI0606170 A BRPI0606170 A BR PI0606170A BR PI0606170 A2 BRPI0606170 A2 BR PI0606170A2
Authority
BR
Brazil
Prior art keywords
rosuvastatin
purification
diastereomeric
diastereomeric purification
diastereomerically pure
Prior art date
Application number
BRPI0606170-2A
Other languages
English (en)
Inventor
Valerie Niddam-Hildesheim
Anna Balanov
Kobi Chen
Natalia Shenkar
Original Assignee
Teva Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma Ltd filed Critical Teva Pharma Ltd
Publication of BRPI0606170A2 publication Critical patent/BRPI0606170A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

PURIFICAçãO DIASTEREOMéRICA DE ROSUVASTATINA. A invenção refere-se a rosuvastatina diastereomericamente pura e processos para preparação de rosuvastatina diastereomericamente pura e seus intermediários. Fórmula (I)
BRPI0606170-2A 2005-10-03 2006-09-12 purificação diastereomérica de rosuvastatina BRPI0606170A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72349105P 2005-10-03 2005-10-03
US73297905P 2005-11-02 2005-11-02
PCT/US2006/035711 WO2007040940A1 (en) 2005-10-03 2006-09-12 Diastereomeric purification of rosuvastatin

Publications (1)

Publication Number Publication Date
BRPI0606170A2 true BRPI0606170A2 (pt) 2009-06-02

Family

ID=37731511

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606170-2A BRPI0606170A2 (pt) 2005-10-03 2006-09-12 purificação diastereomérica de rosuvastatina

Country Status (9)

Country Link
US (2) US20090187026A1 (pt)
EP (1) EP1817293A1 (pt)
JP (1) JP2008526897A (pt)
KR (2) KR20090113920A (pt)
BR (1) BRPI0606170A2 (pt)
CA (1) CA2624801A1 (pt)
IL (1) IL187949A0 (pt)
TW (1) TW200804305A (pt)
WO (1) WO2007040940A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2007125547A2 (en) 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
ES2567171T3 (es) 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
WO2008053334A2 (en) * 2006-10-31 2008-05-08 Aurobindo Pharma Limited An improved process for preparing rosuvastatin calcium
WO2008096257A1 (en) * 2007-02-08 2008-08-14 Aurobindo Pharma Limited An improved process for preparation of rosuvastatin calcium
US7884226B2 (en) 2007-07-12 2011-02-08 Teva Pharmaceutical Industries, Ltd. Purification of rosuvatatin intermediate by thin film evaporation and chemical method
EP2022784A1 (en) * 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
WO2009143776A1 (zh) * 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
WO2010035284A2 (en) * 2008-09-26 2010-04-01 Matrix Laboratories Ltd An improved process for the preparation of rosuvastatin calcium
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
EP2467363A1 (en) 2009-08-17 2012-06-27 Aurobindo Pharma Limited Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
EP2383260A3 (en) * 2010-04-30 2011-12-28 Dipharma Francis S.r.l. Process for the preparation of statins
ITMI20100753A1 (it) * 2010-04-30 2011-10-31 Dipharma Francis Srl Procedimento per la preparazione di statine
HU230987B1 (hu) * 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
CN104230817B (zh) * 2013-06-19 2016-09-14 南京欧信医药技术有限公司 3，5-二羟基庚-6-烯酸衍生物的制备方法
CN109580789B (zh) * 2017-09-28 2021-06-22 安徽省庆云医药股份有限公司 一种液相色谱法分离测定瑞舒伐他汀叔丁酯及其光学异构体的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189164A (en) * 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5218138A (en) * 1992-09-02 1993-06-08 Rhone-Poulenc Rorer Pharmaceuticals Inc. Stereoselective reduction of 3-hydroxyket-1-ones to 1,3-syn-dihydroxylated compounds
JPH08301864A (ja) * 1995-05-09 1996-11-19 Toyobo Co Ltd α−オキシ酸の分子間環状ジエステルの精製方法
US5741934A (en) * 1996-04-10 1998-04-21 Sandler; Stanley R. Preparation of primary mercaptans
DE19841342A1 (de) * 1998-09-10 2000-04-20 Merck Patent Gmbh Neue Reaktivsysteme aus polymerisierbaren Monomeren , die Peroxide und stabilisierten Boralkylverbindungen enthalten
JP4565208B2 (ja) * 2000-03-31 2010-10-20 株式会社クレハ グリコリドの精製方法
KR100511533B1 (ko) * 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
US20050222415A1 (en) * 2002-05-21 2005-10-06 Yatendra Kumar Process for the preparation of rosuvastatin
JP2004277396A (ja) * 2003-01-23 2004-10-07 Teijin Chem Ltd 芳香族ポリカーボネートから芳香族ジヒドロキシ化合物と炭酸ジアルキルを得る方法
WO2004103977A2 (en) * 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
CA2537271A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
CN1886383A (zh) * 2003-10-22 2006-12-27 兰贝克赛实验室有限公司 无定形罗苏伐他汀钙的制备方法
CA2550742A1 (en) * 2003-12-24 2005-07-14 Teva Pharmaceutical Industries Ltd. Process for preparation of statins with high syn to anti ratio
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
JP2007508379A (ja) * 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法

Also Published As

Publication number Publication date
WO2007040940A1 (en) 2007-04-12
KR20090113920A (ko) 2009-11-02
KR20070085667A (ko) 2007-08-27
TW200804305A (en) 2008-01-16
EP1817293A1 (en) 2007-08-15
IL187949A0 (en) 2008-03-20
US20100197916A1 (en) 2010-08-05
KR101019450B1 (ko) 2011-03-07
CA2624801A1 (en) 2007-04-12
US20090187026A1 (en) 2009-07-23
JP2008526897A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
BRPI0606170A2 (pt) purificação diastereomérica de rosuvastatina
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
TW200624426A (en) BACE inhibitors
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
EA201270149A1 (ru) Ингибиторы bace
HK1135103A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
GB0508318D0 (en) Organic compounds
DE602006009789D1 (de) Acetylenderivate
TW200700064A (en) Novel compounds
MX2011011272A (es) Procesos e intermediarios.
EA201000329A1 (ru) Циклические депсипептиды
MX2012007341A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
ATE517869T1 (de) Herstellung substituierter morphinan-6-one und salzen und zwischenprodukten davon
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
MX2011012533A (es) Espiro-epoxidos como productos intermedios.
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
UA93387C2 (ru) Производные пиримидина и их применение b качестве открывателей калиевых каналов kcnq
MX2008001428A (es) Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
DE602006006030D1 (de) Neue makrolide

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.